logo  
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

Rexahn Pharmaceuticals (RNN) Continues to Spike on Potential Cancer Pill, Roth Upgrade

By  +Follow January 13, 2014 10:17AM
Share:
Tickers Mentioned:

Shares in Rexahn Pharmaceuticals (RNN) jumped nearly 40 percent on Monday, continuing a bull-run that has the stock up over 150 percent since Thursday and over 265 percent in the last month on a promising potential cancer treatment and the initiation of relatively bullish coverage from Roth Capital Markets analysts.

RNN’s RX-3117 Could be Alternative for Eli Lilly’s Gemzar

Driving the current growth-spurt is the announcement of the initation of Phase 1b to study the safety and efficacy of RX-3117, Rexahn’s lead drug candidate, in cancer patients with solid tumors. The hype surrounding RX-3117 is considerable given that it has to potential to function as an oral to Eli Lilly’s (LLY) Gemzar.

"The initiation of this Phase I clinical trial of RX-3117 represents an important milestone for Rexahn," said CEO Peter D. Suzdak, Ph.D. "This compound is exciting to work with, as it has a unique profile with demonstrated activity against gemcitabine-resistant human cancer cells. We were pleased to see reduced side effect liability and oral bioavailability in cancer patients in our initial exploratory Phase I clinical trial conducted in Europe, and we believe that RX-3117 may represent a significant advancement in the treatment of cancer patients with solid tumors."

Gemzar is an injectable drug that results in resistance for 1 out of 4 patients, making an alternative that functions in pill form one with considerable commercial potential.

Analyst Seems Convinced

Also helping boost shares over the past few days was the news from Thursday that Roth Capital Markets’ Joe Pantiginis had initiated coverage on the stock at a “buy” rating with a price target of $3, still nearly double the current share price even after the spike in price.

Along with the considerable potential for RX-3117, the company boasts nearly $15 million in cash as well as over $5 million in new funding, giving it enough money to carry it for two years.

 

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions.


Signup for our daily newsletter and get our best articles emailed right to you!

Results for rnn
ThePennyCommand.com
22 Oct 14 11:45:37
http://t.co/rCFETx8Oyc SwingKing: Anyone still in $RNN?: SwingKing http://t.co/Vu0xzfhIx6 http://t.co/rCFETx8Oyc
Vitor
22 Oct 14 11:35:05
$RNN on watch, volume
TheNewGekko
22 Oct 14 11:28:45
$RNN looking good.. Nice support around .69 - .71 Long and strong!
Andrés De Sousa E.
22 Oct 14 07:54:47
$RNN half daily vol and up 5% ...someone is buying hard
Stock Status
22 Oct 14 07:10:22
GREEN! $TTNP http://t.co/juihUiv41A $RNN http://t.co/iE34KlXG3e $PRAN http://t.co/er9pRC83sT $IMUC http://t.co/4en6IJq2wn
MoneyEmpire
22 Oct 14 06:49:22
$RNN nice to see in green dress
hotpennystockalert
22 Oct 14 02:03:53
Dollar$OnPennies: $RNN Gallery View http://t.co/ZXc21pbVeq
explodeprofits
22 Oct 14 02:03:37
Dollar$OnPennies: $RNN Gallery View http://t.co/m4LpvhN2o8
_tr8dr_
21 Oct 14 12:07:13
$RNN dead stock
WallStreet Pennies
21 Oct 14 01:38:37
Dollar$OnPennies: $RNN Gallery View http://t.co/UggjcobHyn
mystockchoice
21 Oct 14 01:34:40
Dollar$OnPennies: $RNN Gallery View http://t.co/rjEERFcDgw
Stephen P Kendal
20 Oct 14 08:15:15
$RNN #UnderValued #MktCap=$124.78M. #52WkH/L=$1.85/$0.37. #LowTarget=$1.00 +43%. #MeanTarget=$2.20 +214%. Price=$0.70. #BuyRec #12. LT=⇗
THEONESTOCK
20 Oct 14 06:27:56
STOCKS TO WATCH THIS WEEK: $DLIA $HTM $KWK $LEI $ZBB $RNN
explodeprofits
20 Oct 14 02:33:33
Dollar$OnPennies: $RNN Gallery View http://t.co/bdYvBtmV9v
Schwarzgerät
19 Oct 14 18:56:41
@sgerat RX-3117 data expected in 2014Q4/2015Q1. $RNN
Schwarzgerät
19 Oct 14 18:55:11
$RNN Rexahn milestone events for remaining year 2014. #HighVolatility #HighRiskReward #ClinicalData http://t.co/HPiKRPMatQ
Stocks News&Markets
18 Oct 14 10:01:40
lx21 made $55,733 on $RNN -Check it out! http://t.co/WqX5rSCDIW Learn #howtotrade http://t.co/axK8SMSgo9 $COCO $HDSN $BIOF $DLIA $LIME
kenr0966
17 Oct 14 20:34:39
RT @DayTradersGroup: Stochastic Bullish Crossovers http://t.co/pqsiM7anI8 $TFX $VTR $STZ $STJ $SYK $RNN $WYY $AAPL $PCLN $QQQ $FB $TWTR $WF…
Day Traders Group
17 Oct 14 16:43:17
Stochastic Bullish Crossovers http://t.co/pqsiM7anI8 $TFX $VTR $STZ $STJ $SYK $RNN $WYY $AAPL $PCLN $QQQ $FB $TWTR $WFC $MU $DD & More
Momz Day Trading
17 Oct 14 08:33:48
$RNN in a down trend
Stephen P Kendal
16 Oct 14 15:47:09
$RNN #UnderValued #MktCap=$127.27M. #52WkH/L=$1.85/$0.37. #LowTarget=$1.00 +41%. #MeanTarget=$2.20 +210%. Price=$0.71. #BuyRec #14. LT=⇗
BioInvestor
16 Oct 14 13:52:31
@BioInvestor2013 Bioinvest expect here more than 300 % gain !! Lemtrada rights from Sanofi will be approved !!! $CPRX $RNN $ISR $IBIO
Andrés De Sousa E.
16 Oct 14 09:06:03
$RNN adding more here
S_ta__nderSeibe
16 Oct 14 07:00:15
RT @MMauriliStillma: ☯Gain Followers ☯RT This ☯MUST FOLLOW ME I FOLLOW BACK ☯Follow everyone who rts ☯Gain #NowPlayingJalenMcMillanUntil…
Blackmore_La_zo
16 Oct 14 06:48:12
RT @MMauriliStillma: ☯Gain Followers ☯RT This ☯MUST FOLLOW ME I FOLLOW BACK ☯Follow everyone who rts ☯Gain #NowPlayingJalenMcMillanUntil…
NNiermanHymiee
16 Oct 14 06:40:40
RT @MMauriliStillma: ☯Gain Followers ☯RT This ☯MUST FOLLOW ME I FOLLOW BACK ☯Follow everyone who rts ☯Gain #NowPlayingJalenMcMillanUntil…
K__ylil_aGarret
16 Oct 14 06:29:11
RT @MMauriliStillma: ☯Gain Followers ☯RT This ☯MUST FOLLOW ME I FOLLOW BACK ☯Follow everyone who rts ☯Gain #NowPlayingJalenMcMillanUntil…
ChafeeShih01523
16 Oct 14 06:28:08
RT @MMauriliStillma: ☯Gain Followers ☯RT This ☯MUST FOLLOW ME I FOLLOW BACK ☯Follow everyone who rts ☯Gain #NowPlayingJalenMcMillanUntil…
K. Trox
15 Oct 14 06:15:52
Watchlist: $TKMR $BCRX $NNVC $SIMH $AEMD $ABPI $ABIO $HEB $RNN $AEZS $NAVB $RCPI $MDGN $PTIE $ETRM $DARA $OXGN $MSTX $FSI $DEJ $SFLY
				
				
By  +Follow January 13, 2014 10:17AM
Share:

Comments

 

blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.